X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union
Go back to X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union| (NASDAQ: XFOR) | Delayed: 4.22 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.22 | 52 Week High | $ | |||
| Open | $4.22 | 52 Week Low | $ | |||
| Day High | $4.43 | P/E | N/A | |||
| Day Low | $4.17 | EPS | $ | |||
| Volume | 267,258 | |||||
